193,830 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 193,830 shares of the company's stock, valued at approximately $2,438,000. Lisanti Capital Growth LLC owned 0.20% of ARS Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers boosted its stake in shares of ARS Pharmaceuticals by 2.9% in the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after purchasing an additional 1,824 shares during the period. Levin Capital Strategies L.P. raised its stake in shares of ARS Pharmaceuticals by 56.2% in the fourth quarter. Levin Capital Strategies L.P. now owns 467,627 shares of the company's stock valued at $4,933,000 after acquiring an additional 168,201 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in ARS Pharmaceuticals in the fourth quarter valued at $175,000. Steward Partners Investment Advisory LLC boosted its holdings in ARS Pharmaceuticals by 47.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 38,050 shares of the company's stock valued at $401,000 after purchasing an additional 12,200 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in ARS Pharmaceuticals by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company's stock worth $4,510,000 after purchasing an additional 3,530 shares in the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on SPRY. Scotiabank began coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. Wall Street Zen raised shares of ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, Director Brent L. Saunders sold 120,000 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total value of $1,710,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the sale, the insider directly owned 89,613 shares of the company's stock, valued at $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,078,120 shares of company stock worth $18,385,038. 33.50% of the stock is owned by insiders.

ARS Pharmaceuticals Stock Up 4.1%

NASDAQ SPRY traded up $0.66 during trading on Wednesday, reaching $16.75. 1,284,404 shares of the company's stock were exchanged, compared to its average volume of 1,336,505. The company has a 50 day moving average price of $14.71 and a two-hundred day moving average price of $13.09. The stock has a market cap of $1.65 billion, a P/E ratio of -104.68 and a beta of 0.90. ARS Pharmaceuticals, Inc. has a 1 year low of $8.65 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. On average, equities research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.